Akebia Therapeutics, Inc. (AKBA) Form 8-K — Oct 14, 2026
Akebia Therapeutics announced that Chief Commercial Officer Nicholas Grund will resign effective November 6, 2026, citing personal reasons. Grund signed a Consulting Agreement dated October 13, 2026 under which he will provide advisory services through April 30, 2027, paid at an hourly rate, with termination provisions on 10 days' (company) or 30 days' (Grund) notice.
Key figures
- Consulting Period End
- 2027-04-30
- Resignation Effective Date
- 2026-11-06
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.